Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Fredrik Karlsson, MD, Angelo Modica, MD, Thomas Mooe, MD, PhD

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study Lynnette.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

An assessment by the Statin Liver Safety Task Force: 2014 update

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Diagnosis and Management of Chronic Kidney Disease

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Clinical Approach to the Patient With Abnormal Liver Test Results

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis Robert Wolk, MD, PhD, DSc, Ehrin J.

Matei Neagu, PhD, Daniel Coca, PhD, Albert C.M. Ong, DM

Liver Failure Secondary to Amyloid Light-Chain Amyloidosis

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

Chronic Kidney Disease in Diabetes

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Juice Plus or Toxicity Plus

Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States Constance E. Ruhl, James E.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

A New Clinical Prediction Tool for 5-Year Kidney Transplant Outcome

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

An assessment by the Statin Intolerance Panel: 2014 update

Your Kidneys May Outlive You

The Natural Course of Microalbuminuria among African Americans with Type 2 Diabetes: A 3-Year Study Mohamed G. Atta, MD, MPH, Kesha Baptiste-Roberts,

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Erratum American Journal of Kidney Diseases

Salt and Hypertension American Journal of Kidney Diseases

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis Xiaole Su, MD, Lu Zhang, MD, Jicheng Lv, MD, PhD, Jinwei Wang, PhD,

Higher triglyceride level predicts hyperuricemia: A prospective study of 6-year follow-up Yuan Zhang, Fengjiang Wei, PhD, Chen Chen, MD, Chunyou Cai,

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease:

Arun Rajan, MD, David Kotlyar, MD, Giuseppe Giaccone, MD, PhD

Laboratory parameter profiles among patients with cystic fibrosis

Kathleen D. Liu, Jingrong Yang, Thida C. Tan, David V

Quiz Page July 2012 American Journal of Kidney Diseases

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Volume 70, Issue 3, Pages (March 2019)

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease Joan C. Lo, Glenn M. Chertow, Alan S. Go, Chi-Yuan.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Drug Dose Adjustments in Patients With Renal Impairment

Methods for guideline development

Lesley A. Stevens, MD, MS, Nicholas Stoycheff, MD

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Volume 80, Issue 10, Pages (November 2011)

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Ann M. O'Hare, MA, MD American Journal of Kidney Diseases

Adiponectin: good, bad, or just plain ugly?

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

LINDA S. SNYDER, M.D., RUSSELL I. HEIGH, M.D., MONTE L. ANDERSON, M.D.

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child

Presentation transcript:

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial Shun Ishibashi, MD, PhD, Hidenori Arai, MD, PhD, Koutaro Yokote, MD, PhD, Eiichi Araki, MD, PhD, Hideki Suganami, PhD, Shizuya Yamashita, MD, PhD Journal of Clinical Lipidology Volume 12, Issue 1, Pages 173-184 (January 2018) DOI: 10.1016/j.jacl.2017.10.006 Copyright © 2017 National Lipid Association Terms and Conditions

Figure 1 Change from baseline over time in liver enzymes. Data are presented as mean changes from baseline in liver enzymes in the pemafibrate 0.2 mg/d (⧫), pemafibrate 0.4 mg/d (■), and fenofibrate 106.6 mg/d (▲) groups. (A) Alanine aminotransferase (ALT); (B) aspartate aminotransferase (AST); (C) gamma-glutamyltransferase (γ-GT); (D) alkaline phosphatase (ALP). Parentheses indicate the number of patients. Error bars indicate standard deviation. ∗∗∗P < .001, ∗∗P < .01, ∗P < .05 vs baseline tested by 1-sample t-test. †††P < .001, ††P < .01, †P < .05 vs fenofibrate tested by analysis of covariance. Journal of Clinical Lipidology 2018 12, 173-184DOI: (10.1016/j.jacl.2017.10.006) Copyright © 2017 National Lipid Association Terms and Conditions

Figure 2 Change from baseline over time in parameters of kidney function. Data are presented as mean changes from baseline in parameters of kidney function in the pemafibrate 0.2 mg/d (⧫), pemafibrate 0.4 mg/d (■), and fenofibrate 106.6 mg/d (▲) group. (A) Estimated glomerular filtration rate (eGFR); (B) serum creatinine (SCr); (C) cystatin C. Parentheses indicate the number of patients. Error bars indicate standard deviation. ∗∗∗P < .001, ∗∗P < .01, ∗P < .05 vs baseline tested by 1-sample t-test. †††P < .001, ††P < .01, †P < .05 vs fenofibrate tested by analysis of covariance. Journal of Clinical Lipidology 2018 12, 173-184DOI: (10.1016/j.jacl.2017.10.006) Copyright © 2017 National Lipid Association Terms and Conditions